IN8bio Statistics
Want to see INAB full AI Analyst Report?
IN8bio (INAB) Stock Statistics & Valuation Metrics
Total Valuation
IN8bio has a market cap or net worth of $9.73M. The enterprise value is $14.68M.
- Market Cap
- $9.73M
- Enterprise Value
- $14.68M
Share Statistics
IN8bio has 10,808,292 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,808,292
- Owned by Insiders
- 4.59%
- Owned by Institutions
- 5.49%
Financial Efficiency
IN8bio’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -65.46%.
- Return on Equity (ROE)
- -0.71
- Return on Assets (ROA)
- -0.60
- Return on Invested Capital (ROIC)
- -65.46%
- Return on Capital Employed (ROCE)
- -0.68
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.14M
- Employee Count
- 17
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of IN8bio is -0.69. IN8bio’s PEG ratio is -0.00.
- PE Ratio
- -0.69
- PS Ratio
- 0.00
- PB Ratio
- 1.20
- Price to FCF
- -0.63
- Price to Operating Cash Flow
- -1.15
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, IN8bio had revenue of 0 and earned -19.44M in profits. Earnings per share was -4.44.
- Revenue
- 0
- Gross Profit
- -2.50M
- Operating Income
- -19.86M
- Pretax Income
- -19.44M
- Net Income
- -19.44M
- EBITDA
- -16.94M
- Earnings Per Share (EPS)
- -4.44
Cash Flow
In the last 12 months, operating cash flow was -14.76M and capital expenditures -241,000, giving a free cash flow of -15.00M billion.
- Operating Cash Flow
- -14.76M
- Free Cash Flow
- -15.00M
- Free Cash Flow per Share
- -0.77
Dividends & Yields
IN8bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -155.80%
- Earnings Yield
- -111.88%
Stock Price Statistics
- Beta
- 1.49
- 52-Week Price Change
- -48.15%
- 50-Day Moving Average
- 1.13
- 200-Day Moving Average
- 1.40
- Relative Strength Index (RSI)
- 37.91
- Average Volume (3m)
- 48.86K
Important Dates
IN8bio upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
IN8bio as a current ratio of 8.82, with Debt / Equity ratio of 10.10%
- Current Ratio
- 8.82
- Quick Ratio
- 8.82
- Debt to Market Cap
- 0.15
- Net Debt to EBITDA
- 1.44
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, IN8bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
IN8bio EV to EBITDA ratio is 0.09, with an EV/FCF ratio of 0.11.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.09
- EV to Free Cash Flow
- 0.11
- EV to Operating Cash Flow
- 0.11
Balance Sheet
IN8bio has $13.97M in cash and marketable securities with $2.75M in debt, giving a net cash position of $11.22M billion.
- Cash & Marketable Securities
- $13.97M
- Total Debt
- $2.75M
- Net Cash
- $11.22M
- Net Cash Per Share
- $1.04
- Tangible Book Value Per Share
- $0.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for IN8bio is $5.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $5.50
- Price Target Upside
- 531.46% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 81.16%
Scores
- Smart Score
- ―
- AI Score
- 43
